# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Shows nearly 10x advantage in overall survival at 36 months based on ctDNA status and affirms Signatera's ability to pred...
Piper Sandler analyst David Westenberg reiterates Natera (NASDAQ:NTRA) with a Overweight and maintains $150 price target.
Presentations include abstracts from the GALAXY arm of the CIRCULATE-Japan trial, along with new data in Breast Cancer and Squa...
Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $130 to $145.
Morgan Stanley analyst Tejas Savant maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $125 t...